Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique

被引：0
|
作者：
Bonny Parkinson
Sallie-Anne Pearson
Rosalie Viney
机构：
[1] University of Technology,Centre for Health Economics Research and Evaluation (CHERE)
[2] Sydney,Pharmacoepidemiology and Pharmaceutical Policy Research Group, Faculty of Pharmacy
[3] The University of Sydney,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Economics; Cost-utility analysis; Cost-effectiveness analysis; Breast neoplasms; Metastatic; Trastuzumab; I18; D61;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：93 / 112
页数：19
相关论文
共 50 条
  • [31] Trastuzumab - A review of its use in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, GL
    Keam, SJ
    DRUGS, 2006, 66 (04) : 449 - 475
  • [32] Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
    You, Shuhui
    Xie, Yizhao
    Sang, Die
    Luo, Ting
    Yuan, Peng
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [33] Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
    Irelli, Azzurra
    Ceriello, Laura
    Patruno, Leonardo Valerio
    Tessitore, Alessandra
    Alesse, Edoardo
    Cannita, Katia
    Fabiani, Donatello
    BIOMEDICINES, 2024, 12 (01)
  • [34] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [35] Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
    Ventura, Ignacio
    Salcedo, Nerea Pinilla
    Perez-Bermejo, Marcelino
    Perez-Murillo, Javier
    Tejeda-Adell, Manuel
    Tomas-Aguirre, Francisco
    Legidos-Garcia, Maria Ester
    Murillo-Llorente, Maria Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [36] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [37] Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis
    Collova, Elena
    Ferzi, Antonella
    Scandurra, Giuseppa
    Aurilio, Gaetano
    Torri, Valter
    Porcu, Luca
    Sano, Maria Vita
    Taibi, Eleonora
    Foglietta, Jennifer
    Generali, Daniele
    Andreis, Daniele
    Dazzani, Maria Chiara
    Bramati, Annalisa
    Marcon, Ilaria
    Atzori, Francesco
    Cinieri, Saverio
    Tondulli, Luca
    Grasso, Donatalla
    Nole, Franco
    Petrella, Maria Cristina
    Gori, Stefania
    La Verde, Nicla
    TUMORI, 2014, 100 (04) : 426 - 431
  • [38] CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Baselga, Jose
    Swain, Sandra M.
    CLINICAL BREAST CANCER, 2010, 10 (06) : 489 - 491
  • [39] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    BioDrugs, 2006, 20 : 259 - 262
  • [40] Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment
    Genuino, Anne Julienne
    Gloria, Mac Ardy Junio
    Chaikledkaew, Usa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1001 - 1010
12345